Skip to main content
Erschienen in: Antimicrobial Resistance & Infection Control 1/2015

Open Access 01.12.2015 | Poster presentation

Developing a model for analysis the extra costs associated with surgical site infections (SSIs): an orthopaedic and traumatological study run by the Gaetano Pini Orthopaedic Institute

verfasst von: M Nobile, P Navone, A Orzella, R Colciago, F Auxilia, G Calori

Erschienen in: Antimicrobial Resistance & Infection Control | Sonderheft 1/2015

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN

Introduction

Over the years, the Gaetano Pini Orthopaedic Institute has implemented several projects in the hope of preventing healthcare-associated infections (HAIs).
In particular, the institute participated in a long-term project monitoring arthroplasty-associated SSIs in 2010 (the ISChIA study), funded by the Italian Society of Hygiene’s GISIO (the Italian Study Group of Hospital Hygiene) which involved several different hospitals and enabled it to assess the frequency of SSIs in this kind of operation and identify potential risk factors.

Objectives

This project aims to develop a model for assessing the direct cost of SSIs borne by the hospital and the regional health service. The study was run by the Gaetano Pini Orthopaedic Institute in partnership with Aon Hewitt Risk & Consulting, AGRC Italy and the University of Milan.

Methods

Seven patients who developed an SSI during the ISChIA project were chosen for the study. A model for analysing the additional costs of an SSI was developed which started by considering two different circumstances: hospital admission with changes to the DRG attributable to the SSI and cases where the extra costs could be traced back to subsequent hospital admissions or outpatient procedures.
Moreover, an analysis aimed at establishing the costs borne by the hospital and those borne by the regional health service was carried out.

Results

The total extra cost of the SSIs analysed came to over €32,000, with an average cost per SSI of approximately €9,560 and costs ranging from €3,411 to €22,273 for hospital admissions due to infections. The cost of €57,419 was borne by the regional health service – with an average cost per case of €8,202 – while the hospital had to pay €8,513 with an average cost per case of €1,216.

Conclusion

This project has allowed us to develop a quantitative model for assessing the extra costs associated with SSIs. Certain variables that could lead to an underestimation of the results need to be taken into consideration.
Of these, the lack of post-discharge information and the fragmentary nature of such data could affect the clinical outcome and the possibility of quantifying the true cost.

Disclosure of interest

None declared.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​4.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Metadaten
Titel
Developing a model for analysis the extra costs associated with surgical site infections (SSIs): an orthopaedic and traumatological study run by the Gaetano Pini Orthopaedic Institute
verfasst von
M Nobile
P Navone
A Orzella
R Colciago
F Auxilia
G Calori
Publikationsdatum
01.12.2015
Verlag
BioMed Central
DOI
https://doi.org/10.1186/2047-2994-4-S1-P68

Weitere Artikel der Sonderheft 1/2015

Antimicrobial Resistance & Infection Control 1/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.